Overview

An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome

Status:
Recruiting
Trial end date:
2024-03-06
Target enrollment:
Participant gender:
Summary
Stoke Therapeutics is evaluating the safety and tolerability of single and multiple ascending doses of STK-001 in patients with Dravet syndrome. Change in seizure frequency, overall clinical status, and quality of life will be measured as secondary endpoints in this open-label study.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Stoke Therapeutics, Inc